Sofinnova Investments’s Aclaris Therapeutics ACRS Stock Holding History

Sofinnova Investments’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,911,573	Closed	-$12.4M	–	67
2020 Q4	$12.4M	Hold	1,911,573	–	–	0.74%	27
2020 Q3	$4.91M	Hold	1,911,573	–	–	0.36%	46
2020 Q2	$3.1M	Hold	1,911,573	–	–	0.2%	61
2020 Q1	$1.99M	Hold	1,911,573	–	–	0.18%	54
2019 Q4	$3.61M	Hold	1,911,573	–	–	0.26%	50
2019 Q3	$2.06M	Hold	1,911,573	–	–	0.19%	57
2019 Q2	$4.19M	Hold	1,911,573	–	–	0.38%	42
2019 Q1	$11.4M	Hold	1,911,573	–	–	1.1%	19
2018 Q4	$14.1M	Buy	1,911,573 +372,093	+24%	+$3.84M	1.76%	15
2018 Q3	$22.4M	Hold	1,539,480	–	–	1.99%	13
2018 Q2	$30.7M	Hold	1,539,480	–	–	3.48%	9
2018 Q1	$27M	Buy	+1,539,480	New	+$32.6M	4.64%	9

Other funds holding ACRS

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Sofinnova Investments's ACRS Position: Q1 2021 in Review

Sofinnova Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2021, closing a stake of 1,911,573 shares — an estimated $12.4M sold.

Sofinnova Investments first reported a position in ACRS in Q1 2018 and held it in 12 quarters. The position peaked at $30.7M in Q2 2018. 97 funds tracked by Wall St. Rank hold ACRS as of Q1 2021.

Sofinnova Investments reported no remaining Aclaris Therapeutics position as of Q1 2021 after selling out during the quarter.
Sofinnova Investments sold 1,911,573 Aclaris Therapeutics shares in Q1 2021, an estimated $12.4M.
Sofinnova Investments first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 12 quarters.
Sofinnova Investments's Aclaris Therapeutics position peaked at $30.7M in Q2 2018.
97 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2021.

Based on Sofinnova Investments's 13F filing for Q1 2021, filed 14 May 2021.